Acalabrutinib patient study for early access CLL in the UK
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This observational study follows adults in the UK who started acalabrutinib through an early access program for chronic lymphocytic leukemia (CLL). It aims to learn what happens in real-world care after starting the medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with CLL (or sometimes small lymphocytic lymphoma, SLL).
- You did not take acalabrutinib before (you started it for the first time).
- You started acalabrutinib through the UK Early Access Programme (not routine care).
- Your first dose was between April 1, 2020 and April 1, 2021.
- You are 18 years old or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs for people with CLL or SLL whose cancer returned after first treatment with a similar type of therapy. The goal is to see if this approach works well with a fixed treatment duration.
This study follows people with CLL who are starting acalabrutinib (a targeted pill) for the first time, either as their first treatment or after previous therapies. The goal is to see how well it works in everyday medical practice.
This study looks at how acalabrutinib, a targeted therapy for chronic lymphocytic leukemia (CLL), works in real-life settings in Spain. It aims to see how well it helps people who are starting treatment for the first time or switching due to side effects.
This Phase 2 trial studies whether acalabrutinib, and optionally adding obinutuzumab, can control early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see how well these treatments work and how safe they are in people who have not had prior treatment.
This study is looking at how well acalabrutinib works in real-world patients who have mantle cell lymphoma (MCL) or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). If you have one of these types of blood cancer and have not had certain other treatments, you may be able to join.
This trial tests a different targeted drug, acalabrutinib, for people with CLL or SLL who developed heart problems (like atrial fibrillation) while taking ibrutinib. The goal is to see if acalabrutinib can control the cancer without causing the same heart side effects.
Hear when a new Chronic Lymphocytic Leukemia, CLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.